Clinical Trials
5
Active:0
Completed:1
Trial Phases
2 Phases
Early Phase 1:1
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Early Phase 1
1 (20.0%)Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML
Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 15
- Registration Number
- NCT05334693
- Locations
- 🇧🇾
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Minsk Region, Belarus
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Phase 1
Recruiting
- Conditions
- Lymphoblastic B-Cell LymphomaB-cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: CD19 CAR-T-cells
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 10
- Registration Number
- NCT05333302
- Locations
- 🇧🇾
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Minsk Region, Belarus
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 15
- Registration Number
- NCT05272293
- Locations
- 🇧🇾
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Minsk Region, Belarus
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
Phase 1
Completed
- Conditions
- Leukemia, Acute MyeloidLeukemia, Acute Lymphoblastic
- Interventions
- Biological: Expanded Haploidentical Natural Killer cells
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-03-02
- Target Recruit Count
- 10
- Registration Number
- NCT04327037
- Locations
- 🇧🇾
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Minsk Region, Belarus
DNA Vaccination Against Neuroblastoma
Early Phase 1
- Conditions
- Relapsed Neuroblastoma
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2022-03-02
- Target Recruit Count
- 12
- Registration Number
- NCT04049864
- Locations
- 🇧🇾
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Minsk Region, Belarus
News
No news found